Cambridge, United Kingdom

Jonathan Dickens

This inventor holds 1 USPTO granted patent. Top assignee: Chiroscience, Ltd.. Active years: 1998.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Jonathan Dickens

Introduction

Jonathan Dickens is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of therapeutic compounds, particularly in the development of inhibitors for various diseases. His work is characterized by a focus on novel mercaptoalkylpeptidyl compounds, which have promising applications in medicine.

Latest Patents

Jonathan Dickens holds a patent for "Peptidyl compounds and their therapeutic use as inhibitors of." This invention concerns novel mercaptoalkylpeptidyl compounds of formula (I), which are useful inhibitors of matrix metalloproteinase and/or TNF-mediated diseases. These include degenerative diseases and certain cancers. The patent also outlines methods for treating patients suffering from disorders associated with matrix metalloproteinase or TNF activity. He has 1 patent to his name.

Career Highlights

Jonathan has been associated with Chiroscience, Ltd., where he has contributed to various research initiatives. His work has been instrumental in advancing the understanding of therapeutic applications for his patented compounds.

Collaborations

Some of his notable coworkers include Andrew Douglas Baxter and David Alan Owen. Their collaborative efforts have further enhanced the research and development of innovative therapeutic solutions.

Conclusion

Jonathan Dickens is a distinguished inventor whose work in the field of therapeutic compounds has the potential to impact the treatment of serious diseases. His innovative contributions continue to pave the way for advancements in medical science.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…